Day 1 - Wednesday, 22 May

Meeting category
Date(s)
22 May 2019 - 24 May 2019
Location
Rome,
Italy
Organizer

European Meeting on HIV & Hepatitis 2019
Related Enduring Materials
Enduring Materials
Downloads:
Program
Opening session -
Chairs
09:00 CEST
Tribute to Andrea De Luca and Ricardo Camacho
09:15 CEST
Andrea De Luca Lecture: The top 10 important observations of the last year affecting clinical management
09:45 CEST
Resistance to integrase inhibitors
Session 1: The role of the reservoir on clinical decision making -
Chairs

Rolf Kaiser, PhD
University of Cologne, Germany
10:45 CEST
How to measure the reservoir

María José Buzón, PhD
Vall d'Hebron Research Institute, Spain
11.15 CEST
How does the reservoir influence the clinician's decisions
Special Session: Genetic Barrier – Role in HIV Treatment Decision -
Chair
12:00 CEST
Genetic Barrier, Basic Principles
12:20 CEST
Genetic Barrier and Reduced Drug Regimens

Romina Quercia, MD, PhD
ViiV Healthcare, United Kingdom
12:40 CEST
Genetic Barrier – Clinical Cases
Session 2: Role of STI management in HIV prevention -
Chairs

David van de Vijver
-
14.20 CEST
Interplay between PrEP and STI

Cécile Bébéar, MD, PhD
University of Bordeaux, France
Abstract - driven presentations - 14.35
14.35 CEST
First results after 52 weeks of informal PrEP use in a cohort of MSM in Southern Spain.
14:50 CEST
European surveillance of HIV drug resistance to NRTI, NNRTI and INSTI in newly diagnosed individuals using next-generation sequencing.
15:15 CEST
Molecular analysis suggests post-migration HIV-1 acquisition among migrants in Paris, France.
15:30 CEST
Trends of transmitted and acquired hiv-1 drug resistance in patients followed in portuguese hospitals between 2001 and 2017
Marta Pingarilho
Portugal
Session 3: Clinical management of HIV - related abstracts -
Chairs

Anne-Mieke Vandamme
-
16:40 CEST
Remembering Ricardo Camacho: HIV-2 Diagnostics, therapy and resistance testing
Rolf Kaiser, PhD
University of Cologne, Germany
16:55 CEST
Seminal HIV-1 RNA and drug concentrations in DTG+3TC dual therapy (ANRS167 Lamidol)
17:10 CEST
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study
17:25 CEST
High prevalence of the integrase resistance associated accessory mutation L74I in the Russian Federation
17:40 CEST
Fostemsavir (FTR) Week 48 efficacy and evaluation of treatment emergent substitutions in the BRIGHTE study
Max Lataillade
USA
17:55 CEST
Epidemiological study of Doravirine associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy
Day 2 - Thursday, 23 May
Session 4: What's in the pipeline? -
Chairs
08.30 CEST
Presentations from scientists from the industry

Harmony P. Garges, MD, MPH
Vice President and Head, Global Medical Affairs, ViiV Healthcare, USA

Luisa Stamm, MD, PhD
Executive Director, HIV and Emerging Viral Infections, Gilead Sciences, USA

Hanneke Schuitemaker, PhD
Vice President, Head Viral Vaccine Discovery and Translational Medicine, Janssen, The Netherlands
Special Session: Clinical considerations in choosing first-line therapy -
Chair
11:15 CEST
Welcome and introduction

Carlo Federico Perno, MD, PhD
University of Milan, Italy
11:20 CEST
Same day treatment initiation
11:40 CEST
First line therapies: implications for long term resistance
Session 5: Management of viral hepatitis I -
Chairs
Carlo Perno
-
13:15 CEST
Novel compounds for HBV therapy
14:15 CEST
Abstract-driven presentations
The integration of Hepatitis B virus in relevant regions of human genome is a common event in the setting of HBeAg negative chronic infection despite limited liver disease: implications for an altered cell metabolism
Romina Salpini, Italy
The transmission dynamics of acute HCV infections in HIV-positive men who have sex with men in the Netherlands is suitable for targeted risk reduction strategies
Stephanie Popping, the Netherlands
Session 6: Management of viral hepatitis II - 15.45
15.45 CEST
Clinical relevance of HCV rare subtypes
16:15 CEST
Abstract-driven presentations
Clinical and virological characteristics of patients with chronic hepatitis C and failure to a Glecaprevir and Pibrentasvir (G/P) treatment in real world
Federico Garcia, Spain
Retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen after performing a genotypic resistance test: the Italian Vironet C real life experience
Velia Chiara Di Maio
Specific NS5A polymorphisms correlate with hepatocellular carcinoma in cirrhotic patients infected with HCV genotype 1b
Mohammad Altkhatib
Day 3 - Friday, 24 May
Session 7: Clinical management challenges - 08:30
08:30 CEST
The new patient - with what & when
09:30 CEST
The pregnant woman - update
Session 10: Progress in cure / elimination approaches -
Chair
Carlo Perno
-
11:45 CEST
Update on HIV cure research

Linos Vandekerckhove, MD, PhD
University of Gent, Belgium
12:15 CEST
Hepatitis C elimination research
12:45 CEST
Perspectives in HBV cure research
13:30 CEST
Ricardo Camacho Award ceremony and closure of the meeting
Overview
Committees
Support